Long-term evaluation of vascular toxicity in patients with Ph+ leukemias treated with bosutinib.
Jorge E. Cortes
Consultant or Advisory Role - ARIAD; Bristol-Myers Squibb; Novartis; Pfizer; Teva
Research Funding - ARIAD; Bristol-Myers Squibb; Novartis; Pfizer; Teva
Hagop M. Kantarjian
Research Funding - ARIAD; Bristol-Myers Squibb; Novartis; Pfizer
Hanna Jean Khoury
Consultant or Advisory Role - Pfizer
Tim H. Brümmendorf
Consultant or Advisory Role - ARIAD; Bristol-Myers Squibb; Novartis; Pfizer
Honoraria - ARIAD; Bristol-Myers Squibb; Novartis; Pfizer
Research Funding - Novartis
Maureen G. Conlan
Employment or Leadership Position - Pfizer
Kongming Wang
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer
Kolette D. Fly
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer (B)
Mark Shapiro
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer
Jeffrey Howard Lipton
Consultant or Advisory Role - ARIAD; Bristol-Myers Squibb; Novartis; Pfizer; Teva
Stock Ownership - ARIAD
Honoraria - Bristol-Myers Squibb; Novartis
Research Funding - ARIAD; Bristol-Myers Squibb; Novartis; Pfizer; Teva
Jean-Bernard Durand
No relevant relationships to disclose
Carlo Gambacorti-Passerini
Consultant or Advisory Role - Bristol-Myers Squibb; Novartis; Pfizer
Research Funding - Pfizer